(Q42451513)

31 October 2017

title

Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function (English)

1 reference

31 October 2017

1 reference

9

1 reference

31 October 2017

4

Nina Friis-Møller

0 references

Heidi Storgaard

Heidi Storgaard

5

0 references

Steen Bendix Haugaard

Steen B Haugaard

2

0 references

Ove Andersen

Ove Andersen

1

0 references

Jens Ole Nielsen

7

Jens Ole Nielsen

1 reference

31 October 2017

6

Aage Vølund

1 reference

31 October 2017

Ulrik B Andersen

3

1 reference

31 October 2017

Nina Friis-Møller

4

1 reference

31 October 2017

Johan Iversen

8

1 reference

31 October 2017

publication date

1 October 2003

1 reference

31 October 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Metabolism

1 reference

31 October 2017

volume

52

1 reference

31 October 2017

issue

10

1 reference

31 October 2017

page(s)

1343-1353

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

31 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Insulin resistance in the HIV-lipodystrophy syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Insulin resistance: the fundamental trigger of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Calculation of substrate oxidation rates in vivo from gaseous exchange.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

ISEC: a program to calculate insulin secretion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Quantification of beta-cell function during IVGTT in Type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Metabolic effects of indinavir in healthy HIV-seronegative men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Indinavir induces acute and reversible peripheral insulin resistance in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Insulin resistance in skeletal muscles in patients with NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Mechanisms of insulin resistance in non-oxidative glucose metabolism: the role of glycogen synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Influence of body fat distribution on free fatty acid metabolism in obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Effect of long chain triglyceride infusion on glucose metabolism in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

Independent Influence of Age on Basal Insulin Secretion in Nondiabetic Humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900201-4

10.1016/S0026-0495(03)00201-4

7 January 2021

Identifiers

DOI

1 reference

31 October 2017

1 reference